Home » Regions » Global News » Merck, Pfizer collaborate with Dako

Merck, Pfizer collaborate with Dako

Friday, September 25, 2015

As part of the global strategic alliance between Merck, based in Darmstadt, Germany, and Pfizer to jointly develop and commercialize avelumab, an investigational immune checkpoint inhibitor, the companies have announced a collaboration agreement with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).

The three-party agreement, signed recently, enables Dako, Merck and Pfizer work to develop the CDx to assess programmed death-ligand 1 (PD-L1) protein expression levels in tumor tissue and its microenvironment, including tumor-associated immune cells. The investigational CDx is part of the protocols in ongoing clinical trials of avelumab, some of which will be reported at upcoming scientific congresses.

The financial terms of the agreement have not been disclosed.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!